The presence of anti-cyclic citrullinated peptide antibody is associated with magnetic resonance imaging detection of bone marrow oedema in early stage rheumatoid arthritis
Early prediction of erosive joint damage is very important in rheumatoid arthritis (RA) because significant articular damage in patients is evident radiologically within the first few years of the disease. 1 This study was designed to confirm whether anti-cyclic citrullinated peptide antibodies (ant...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 65; no. 1; pp. 133 - 134 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group Ltd and European League Against Rheumatism
01.01.2006
BMJ BMJ Publishing Group LTD BMJ Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Early prediction of erosive joint damage is very important in rheumatoid arthritis (RA) because significant articular damage in patients is evident radiologically within the first few years of the disease. 1 This study was designed to confirm whether anti-cyclic citrullinated peptide antibodies (anti-CCP Ab) define the subset of patients with early stage RA who have bone marrow oedema, observed by magnetic resonance imaging (MRI). Bone marrow oedema is a forerunner of bone erosion on plain radiography, 8 and thus our present data show the additional importance of the presence of anti-CCP Ab at baseline as an indication of future bone erosion in early stage RA. 9 Table 2 Comparison of IgM-RF+ and IgM-RF- patients Variables IgM-RF+ (n = 54) IgM-RF- (n = 26) p Value CRP (mg/ml) 1.5 (2.1) 2.0 (3.3) 0.96* MMP-3 (%) 51.9 34.6 0.23** Number of joints with synovitis 12.1 (5.6) 10.6 (7.8) 0.22* Mean E-rate of 30 joints 7.6 (3.2) 7.6 (2.3) 0.58* Bone marrow oedema % 63.0 42.3 0.08** No 2.7 (3.5) 1.4 (2.7) 0.07* Data are mean (SD) unless stated otherwise. |
---|---|
Bibliography: | PMID:16344500 Correspondence to: Professor K Eguchi eguchi@net.nagasaki-u.ac.jp istex:6933A1A9C5AF12A29264804CE46CEFA78BDFD068 href:annrheumdis-65-133.pdf ark:/67375/NVC-7W3T5CHW-4 local:0650133 SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Correspondence-1 Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism |
ISSN: | 0003-4967 1468-2060 |
DOI: | 10.1136/ard.2005.04138 |